Abstract
Alpha particle-emitting isotopes are being investigated in radioimmunotherapeutic applications because of their unparalleled cytotoxicity when targeted to cancer and their relative lack of toxicity towards untargeted normal tissue. Actinium- 225 has been developed into potent targeting drug constructs and is in clinical use against acute myelogenous leukemia. The key properties of the alpha particles generated by 225Ac are the following: i) limited range in tissue of a few cell diameters; ii) high linear energy transfer leading to dense radiation damage along each alpha track; iii) a 10 day halflife; and iv) four net alpha particles emitted per decay. Targeting 225Ac-drug constructs have potential in the treatment of cancer.
Keywords: Actinium-225, 225Ac, alpha particle-emitter, targeted therapy, monoclonal antibody, radioimmunotherapy, nanomaterials, carbon nanotubes, cancer, 225Ac PRODUCTION, Complexing and Chelating Agent Studies
Current Radiopharmaceuticals
Title: Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
Volume: 4 Issue: 4
Author(s): David A. Scheinberg and Michael R. McDevitt
Affiliation:
Keywords: Actinium-225, 225Ac, alpha particle-emitter, targeted therapy, monoclonal antibody, radioimmunotherapy, nanomaterials, carbon nanotubes, cancer, 225Ac PRODUCTION, Complexing and Chelating Agent Studies
Abstract: Alpha particle-emitting isotopes are being investigated in radioimmunotherapeutic applications because of their unparalleled cytotoxicity when targeted to cancer and their relative lack of toxicity towards untargeted normal tissue. Actinium- 225 has been developed into potent targeting drug constructs and is in clinical use against acute myelogenous leukemia. The key properties of the alpha particles generated by 225Ac are the following: i) limited range in tissue of a few cell diameters; ii) high linear energy transfer leading to dense radiation damage along each alpha track; iii) a 10 day halflife; and iv) four net alpha particles emitted per decay. Targeting 225Ac-drug constructs have potential in the treatment of cancer.
Export Options
About this article
Cite this article as:
A. Scheinberg David and R. McDevitt Michael, Actinium-225 in Targeted Alpha-Particle Therapeutic Applications, Current Radiopharmaceuticals 2011; 4 (4) . https://dx.doi.org/10.2174/1874471011104040306
DOI https://dx.doi.org/10.2174/1874471011104040306 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Effective HIV Vaccine: A Combination of Humoral and Cellular Immunity?
Current HIV Research Multidrug Resistance Protein 4 (MRP4/ABCC4): A Suspected Efflux Transporter for Human’s Platelet Activation
Protein & Peptide Letters Associative Learning, the Hippocampus, and Nicotine Addiction
Current Drug Abuse Reviews Targeting Long Non-Coding RNAs in Nervous System Cancers: New Insights in Prognosis, Diagnosis and Therapy
Current Medicinal Chemistry Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Current Alzheimer Research Co-opting Functions of Cholinesterases in Neural, Limb and Stem Cell Development
Protein & Peptide Letters Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Altered Arginine Metabolism in Cells Transfected with Human Wild-Type Beta Amyloid Precursor Protein (βAPP)
Current Alzheimer Research Endomorphin Derivatives with Improved Pharmacological Properties
Current Medicinal Chemistry Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential
Current Medicinal Chemistry Relevance of Protein Isoforms in Proteomic Studies
Current Proteomics Immunological Mechanisms of Neuropsychiatric Lupus
Current Immunology Reviews (Discontinued) Voltage-Gated Calcium Channels as Targets for the Treatment of Chronic Pain
Current Drug Targets - CNS & Neurological Disorders Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents
Current Neuropharmacology Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics Adenoviral Vectors for Cancer Gene Therapy
Current Genomics On the Interaction of β-Amyloid Peptides and α7-Nicotinic Acetylcholine Receptors in Alzheimer’s Disease
Current Alzheimer Research Compounds Combining Aminoadamantane and Monoterpene Moieties: Cytotoxicity and Mutagenic Effects
Medicinal Chemistry